- Home
- COCP vs PULM Comparison
COCP vs PULM Comparison
Compare COCP & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- PULM
- Stock Information
- Founded
- COCP 2006
- PULM 2003
- Country
- COCP United States
- PULM United States
- Employees
- COCP N/A
- PULM N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- COCP Health Care
- PULM Health Care
- Exchange
- COCP Nasdaq
- PULM Nasdaq
- Market Cap
- COCP 15.4M
- PULM 18.3M
- IPO Year
- COCP N/A
- PULM N/A
- Fundamental
- Price
- COCP $1.07
- PULM $4.81
- Analyst Decision
- COCP Strong Buy
- PULM
- Analyst Count
- COCP 1
- PULM 0
- Target Price
- COCP $6.00
- PULM N/A
- AVG Volume (30 Days)
- COCP 269.2K
- PULM 20.3K
- Earning Date
- COCP 11-12-2025
- PULM 10-16-2025
- Dividend Yield
- COCP N/A
- PULM N/A
- EPS Growth
- COCP N/A
- PULM N/A
- EPS
- COCP N/A
- PULM N/A
- Revenue
- COCP N/A
- PULM $3,000.00
- Revenue This Year
- COCP N/A
- PULM N/A
- Revenue Next Year
- COCP N/A
- PULM $134.88
- P/E Ratio
- COCP N/A
- PULM N/A
- Revenue Growth
- COCP N/A
- PULM N/A
- 52 Week Low
- COCP $1.02
- PULM $1.96
- 52 Week High
- COCP $3.26
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- COCP 32.57
- PULM 49.26
- Support Level
- COCP $1.02
- PULM $4.58
- Resistance Level
- COCP $1.09
- PULM $5.00
- Average True Range (ATR)
- COCP 0.07
- PULM 0.28
- MACD
- COCP -0.01
- PULM 0.00
- Stochastic Oscillator
- COCP 17.24
- PULM 35.11
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).